Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
192.5 USD | -0.96% | -9.21% | -16.79% |
Financials (USD)
Sales 2024 * | 81.74M | Sales 2025 * | 351M | Capitalization | 4.08B |
---|---|---|---|---|---|
Net income 2024 * | -459M | Net income 2025 * | -296M | EV / Sales 2024 * | 48.8 x |
Net cash position 2024 * | 93.53M | Net Debt 2025 * | 116M | EV / Sales 2025 * | 11.9 x |
P/E ratio 2024 * |
-8.35
x | P/E ratio 2025 * |
-13.1
x | Employees | 376 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.04% |
Latest transcript on Madrigal Pharmaceuticals, Inc.
1 day | -5.02% | ||
1 week | -12.54% | ||
Current month | -27.21% | ||
1 month | -21.50% | ||
3 months | -15.55% | ||
6 months | +57.53% | ||
Current year | -15.99% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 11-08-31 |
William Sibold
CEO | Chief Executive Officer | - | 23-09-07 |
Rebecca Taub
FOU | Founder | 71 | 16-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 11-08-31 | |
Julian Baker
CHM | Chairman | 57 | 23-06-14 |
Ken Bate
BRD | Director/Board Member | 73 | 16-07-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.35% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 192.6 | -0.94% | 169 014 |
24-04-25 | 194.4 | -5.02% | 707,188 |
24-04-24 | 204.6 | -6.29% | 575,504 |
24-04-23 | 218.4 | +2.29% | 409,554 |
24-04-22 | 213.5 | +0.68% | 727,326 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.99% | 4.08B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.73% | 22.02B | |
-17.84% | 20.9B | |
-9.03% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- MDGL Stock